Klineo offers an AI-powered platform that connects doctors and patients to facilitate participation in cancer clinical trials. Led by CEO Thomas Peyresblanques and CTO Nicolas Drizard, the company began pilots in 2022 at the Gustave Roussy Institute and launched a national platform for triple negative breast cancer with the Collectif Triplettes Roses. In 2023 Klineo extended its platform to additional cancers including breast, skin, and lymphoma, and aims to cover all cancers by the end of 2024. The startup benefits from support from stakeholders including BPI, the Pfizer Healthcare Hub, Wilco, Onconumérique, PariSanté Campus and Unicancer. Klineo plans to use its new funding to expand operations, extend its solution to different cancer types, and grow its business reach across Europe and the US. The company is headquartered in Paris, France.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2024